Bear - I should probably know this already from extensive prior discussions, so apologies in advance for the continued confusion on my part. Perhaps you could clarify for me and any others as well.

The CKD and VCD subsets of the P3 BoM are secondary endpoints being determined along with the primary endpoint of time to first occurrence of a MACE.  So, are (or could) the CKD and VCD therefore be classified as P2 clinical trials within the P3 BoM trial?  They seem comprehensive enough although I recognize there is likely more to it than that.  However, the clinical trial history chart on the RVX website suggests that the P2 clinical trials will follow the P3 BoM trial, which runs counter to that argument. If the CKD and VCD subsets are then simply ‘exploratory’ with potential P2 trials still to come, then it would seem we still have a long way to go to confirming whether ABL has a positive impact on either of those indications would it not? 

I am just trying to determine how much stock we can put into the CKD and VCD results of this P3 BoM trial if we are still very early in the game with these two indications.  We (I) don’t want to overstate the importance of those results if it’s not warranted.